Researchers are reexamining therapeutic benefits for the first time since over 40 years. of Mind-altering substances such as MDMA (ecstasy), cannabis, and psilocybin. and LSD.
Michael Mithoefer, Bessel van der Kolk, Richard C. Schwartz, William Richards, Daniel McQueen, James W. Hopper, Anne St. Goar, Elizabeth Call, …. – The Use of Mind-Modification Substances – MDMA, Psilocybin, and Marijuana for Treating PTSD and Other Mental Distress
Researchers are returning to the study of therapeutic benefits for the first-time in more than 40 years of Mind-altering substances such as MDMA (ecstasy), cannabis, and psilocybin. and LSD.
In the 1970s, the study was completed. of All psychedelics were made illegal in the United States, despite growing evidence. of Their medical value. The Multidisciplinary Association has grown over the past decade. for Psychedelic Research (MAPS), which has sponsored studies in the United States, has helped to revive psychedelic science. and Around the world, MDMA is available-Assisted therapy for PTSD, and End-of-Life anxiety. The The results were very encouraging and lasted for over 72 months of Follow these instructions-Up with little to no adverse effects
Psychedelics may promote a deepening and Acceleration of Psychotherapeutic therapy. People often find that therapy allows them to have access to their past. and Find peace with the disavowed “exiled” Parts of themselves.
Download immediately Michael Mithoefer, Bessel van der Kolk, Richard C. Schwartz, William Richards, Daniel McQueen, James W. Hopper, Anne St. Goar, Elizabeth Call, …. – The Use of Mind-Modification Substances – MDMA, Psilocybin, and Marijuana for Treating PTSD and Other Mental Distress
Recording the founder is part of this workshop of MAPS will show the evolution of The principal investigator of psychedelic treatment of The Phase I and Results of II-level trials will be discussed and Processes, the PI of The Hopkins psilocybin Study terminally Ill Patients and The promises of a marijuana researcher and pitfalls for This substance. The The Boston MDMA Study Team will share their clinical experiences and applications.
In certain therapeutic settings, psychedelics might prove more effective than many conventional treatments. They may also be safer. and More cost-effective.
Please Note: This is the same content as the 30th Annual International Trauma Conference. You cannot receive this content for yourself-Study credit for If you have attended live workshops, this program is for you.
Course Features
- Lectures 0
- Quizzes 0
- Duration 10 weeks
- Skill level All levels
- Language English
- Students 103
- Assessments Yes
